Fig. 1From: The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patientsPie chart of distribution of BCL9 CNV in HCC patients. The figure shows the copy number distribution of the BCL9 gene. Seven HCC patients (14%) had gain in BCL9 CN, and 43 patients (86%) had no gain in BCL9 CN. Gain: CN gain, no. = 7, % = 14; no gain: no gain in CN, no. = 43, % = 86Back to article page